Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Twist Bioscience Corp (TWST) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/04/2023 8-K Quarterly results
Docs: "Twist Bioscience Reports Fiscal Third Quarter 2023 Financial Results"
02/03/2023 8-K Quarterly results
Docs: "Twist Bioscience Reports Fiscal First Quarter 2023 Financial Results – Revenue of $54.2M in 1QFY23 increased 29% over $42.0M in 1QFY22 – – Orders increased to $64.7M in 1QFY23, an increase of 30% over 1QFY22 –"
11/18/2022 8-K Quarterly results
08/05/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
02/04/2022 8-K Quarterly results
11/22/2021 8-K Quarterly results
Docs: "Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results -- Record Revenues in Fiscal 2021 of $132.3M; Increase of 47% over $90.1M in Fiscal 2020 -- -- Growth Driven by Strength in SynBio, NGS, Biopharma Businesses -- -- Expect Revenue of $183M to $193M for Fiscal 2022 -- SOUTH SAN FRANCISCO, Calif. – November 22, 2021 – Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the fourth quarter and full year fiscal 2021 ended September 30, 2021. “Fiscal 2021 was a transformational year for Twist, as we delivered significant revenue growth by diversifying and expanding our customer base in synbio and NGS, as wel..."
08/06/2021 8-K Quarterly results
Docs: "FISCAL 2021 THIRD QUARTER FINANCIAL RESULTS · Orders: Total orders received for the third quarter of fiscal 2021 were $39.1 million, compared to $24.7 million for the same period of fiscal 2020. · Revenue: Total revenues were $35.0 million for the third quarter of fiscal 2021 compared to $21.2 million for the same period of fiscal 2020. · Cost of Revenues: Cost of revenues for the third quarter of fiscal 2021 was $20.9 million compared to $16.5 million for the same period of fiscal 2020. · Research and Development Expenses: Research and development expenses for the third quarter of fiscal 2021 were $19.8 million compared to $10.4 million for the same period of fiscal 2020. · Selling, General and Administrative Expenses: Selling, general and administrative..."
05/06/2021 8-K Quarterly results
02/04/2021 8-K Quarterly results
11/23/2020 8-K Quarterly results
Docs: "Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2020 Financial Results — Fiscal 2020 Revenues of $90.1M; Increase of 66% over $54.4M in Fiscal 2019 — — Strong Growth in Synthetic Biology, NGS Businesses — — Twist Biopharma Established 13 Partnerships, 8 with Milestones and/or Royalties in FY20 — — Expect Revenue of $110M to $118M for Fiscal 2021 — SOUTH SAN FRANCISCO, Calif. - November 23, 2020 - Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the fourth quarter and full year fiscal 2020 ended September 30, 2020. “We ended our fiscal year with record revenue and orders against the backdrop of a global pandemic and si..."
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
02/06/2020 8-K Quarterly results
Docs: "Twist Bioscience Reports First Quarter Fiscal 2020 Financial Results — First Quarter Fiscal 2020 Revenues of $17.2M; Increase of 49% over First Quarter Fiscal 2019 - — Reaches Settlement Agreement with Agilent in Litigation — SOUTH SAN FRANCISCO, Calif. - February 6, 2020 - Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2020, ended December 31, 2019. In a separate press release issued today, the company announced a settlement agreement with Agilent Technologies in the litigation originally filed against Twist on February 3, 2016. “With the uncertainty of the litigation removed, we have a clear runway ..."
12/11/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report December 11, 2019 Twist Bioscience Corporation Delaware 001-38720 46-205888 681 Gateway Blvd. South San Francisco, CA 94080 719-0671 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13...",
"Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results — Fiscal 2019 Revenues Increase 114% over Fiscal 2018 to $54.4M-- — Continued Strength in Synthetic Biology and NGS Businesses - — Expect FY 2020 Revenues of $80M to $84M - SOUTH SAN FRANCISCO, Calif. - December 11, 2019 - Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the fourth quarter and full year fiscal 2019 ended September 30, 2019. “Throughout fiscal 2019, we continued to drive significant revenue growth across geographies, diversifying sales across customers and our synbio and NGS product lines,” said Emily M. Leproust, Ph.D., CEO and co-..."
08/01/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report August 1, 2019 Twist Bioscience Corporation Delaware 001-38720 46-205888 455 Mission Bay Boulevard South Suite 545 San Francisco, CA 94158 719-0671 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications purs...",
"Twist Bioscience Reports Third Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress — Revenues Increase 108% over Third Quarter 2018 — — Increasing Fiscal 2019 Revenue Guidance to $52 to $53 Million; Adjusting Net Loss Guidance to $102 to $104 Million to Reflect Acceleration of Commercial Organization — — Continued Strength in Synthetic Biology and NGS Businesses — SAN FRANCISCO, Calif. - August 1, 2019 - Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2019 ended June 30, 2019. “We have shipped to more than 1000 synbio and NGS customers in fiscal 2019 and for the thi..."
04/30/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report April 30, 2019 Twist Bioscience Corporation Delaware 001-38720 46-205888 Identification No.) 455 Mission Bay Boulevard South Suite 545 San Francisco, CA 94158 719-0671 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement...",
"Twist Bioscience Reports Second Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress — Reports Record Revenue of $13.6 Million for Second Quarter of Fiscal 2019 — — Increasing Orders Show Sequential Growth in Synthetic Biology and Next-Generation Sequencing Products — — Updates Fiscal 2019 Financial Guidance — SAN FRANCISCO, Calif. - April 30, 2019 - Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2019 ended March 31, 2019. “We continue to post strong topline growth as we extend our reach and diversify our revenue stream from our synbio customers,” said Emily M. Lep..."
02/07/2019 8-K Quarterly results
12/19/2018 8-K Quarterly results
Docs: "Twist Bioscience Reports Fiscal 2018 Fourth Quarter and Full Year Financial Results and Highlights Commercial and Operational Progress"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy